Search

Your search keyword '"Rea D."' showing total 1,228 results

Search Constraints

Start Over You searched for: Author "Rea D." Remove constraint Author: "Rea D."
1,228 results on '"Rea D."'

Search Results

1. Risk of Bowel Obstruction in Patients Undergoing Neoadjuvant Chemotherapy for High-risk Colon Cancer: A Nested Case-control Matched Analysis of an International, Multi-centre, Randomised Controlled Trial (FOxTROT)

2. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

3. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

4. Mindset, Anxiety, and Psychological Well-Being of Saint Mary’s University Senior High School Students.

6. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

7. The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review

8. 142 Elexacaftor-tezacaftor-ivacaftor and spirometry-controlled chest CT scores in children with cystic fibrosis aged 6 to 11

11. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

14. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial

17. 138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial

19. Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity – the OCTAVE trial

20. P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS

21. P700: TREATMENT-FREE REMISSION (TFR) AFTER DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND DEEP MOLECULAR RESPONSE (DMR): FINAL 5-YEAR RESULTS OF DASFREE

22. S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE

24. ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine

25. ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine

27. Managing hematological cancer patients during the COVID-19 pandemic:an ESMO-EHA Interdisciplinary Expert Consensus

29. Test of Parity Doubling in 223Ra and 223Th

31. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

34. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

35. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

38. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

41. Ponatinib in Refractory Ph-Positive Leukemias: A Phase 2 Trial

43. Folic acid supplementation in postmenopausal women with hot flushes: phase III randomised double‐blind placebo‐controlled trial

44. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

Catalog

Books, media, physical & digital resources